ImmunityBio (IBRX) Long-Term Investments (2014 - 2023)

ImmunityBio (IBRX) has 10 years of Long-Term Investments data on file, last reported at $891000.0 in Q4 2023.

• On a quarterly basis, Long-Term Investments rose 6.07% year-over-year to $891000.0 in Q4 2023; TTM through Dec 2023 was $891000.0, a 6.07% increase from a year earlier, with the FY2023 full-year figure at $891000.0, up 6.07% from the prior year.
• Long-Term Investments for Q4 2023 stood at $891000.0, up from $817000.0 in the prior quarter.
• Over the last five years, Long-Term Investments for IBRX reached as high as $9.3 million in Q3 2019 and fell as low as $802000.0 in Q3 2021.
• Historically, Long-Term Investments has averaged $3.1 million across 5 years, with a median of $878000.0 in 2022.
• Across the five-year window, Long-Term Investments soared 1221.86% in 2019 and tumbled 91.33% in 2021, its largest moves.
• Year by year, Long-Term Investments stood at $9.3 million in 2019, then decreased by 15.17% to $7.8 million in 2020, then slumped by 89.53% to $822000.0 in 2021, then grew by 2.19% to $840000.0 in 2022, then gained by 6.07% to $891000.0 in 2023.
• Per Business Quant data, the three most recent Long-Term Investments figures were $891000.0 in Q4 2023, $817000.0 in Q3 2023, and $841000.0 in Q2 2023.